MESSAGE FROM THE CHIEF
Hobart W. Harris, M.D., M.P.H.
Professor of Surgery
Chief, Division of General Surgery
Orlo Clark, M.D.
Professor of Surgery
Contact Information
Education
-
1959-63, Cornell University, B.A., Zoology
-
1963-67, Cornell University, M.D., Medicine
Residencies
-
1967-68, University of California, San Francisco, Intern, Surgery
-
1968-70, University of California, San Francisco, Resident, Surgery
-
1971-72, University of California, San Francisco, Senior Resident, Surgery
-
1972-73, University of California, San Francisco, Chief Resident, Surgery
Fellowships
-
1970-71, Hammersmith Hospital, London, Royal Postgraduate M, Endocrine Surgery
Postdoctoral Training
-
1995, Harvard School of Public Health, Unknown, 2 week Program for Clinical Chiefs
Board Certification
- American Board of Surgery, 1974
Clinical Expertise
- Endocrine surgery
- Surgery of the thyroid, parathyroid, adrenal, and endocrine pancreas
- Reoperative thyroid and parathyroid surgery
- Neck dissection
Research Interests
- Thyroid and other endocrine neoplasms
Biography
Dr. Orlo H. Clark is Professor of Surgery at the University of California San Francisco Mt. Zion Medical Center where he leads the Endocrine Surgical Oncology Program. He is certified by the by the American Board of Surgery. Dr. Clark specializes in Endocrine Surgical conditions; specifically treatment of disorders of the thyroid and parathyroid, as well as, adrenal and endocrine pancreas. He utilizes minimally invasive surgical techniques and open operations with intraoperative parathyroid hormone assay and intraoperative magnification..
Dr. Clark attended Cornell University and Cornell Medical School. He completed his surgical training and residency at UCSF. He also did a year Fellowship at the Royal Postgraduate Medical Center in London in Endocrine Surgery, and joined the UCSF faculty in 1973. He continues to teach medical students, residents, and fellows and has received the Lim Thomas Award and Excellence in Teaching Award distinguishing his outstanding teaching accomplishments at UCSF. He is also recognized as one of the best surgeons in America by several publications, such as Leading Health Professionals of the World and America's Top Doctors.
Dr. Clark was the previous Chief of Surgery at Mt. Zion Medical Center and the Vice Chair of the Department of Surgery. Dr. Clark is recognized as a leader in his field both nationally and internationally. He has been the President of the American Association of Endocrine Surgeons, the American Thyroid Association, the International Association of Endocrine Surgeons, and is currently President Elect of the Pacific Coast Surgical Association. He is an honorary member of the German Surgical Society, the Turkish Endocrine Surgical Society, the Asian Endocrine Surgical Society, and received a Docteur Honoris Causa (Honorary Doctorate) from Poitier University. Dr. Clark has authored and co-authored over 300 journal manuscripts, chapters, and books.
Besides a busy and successful clinical practice, Dr. Clark is actively involved in research focusing on what makes thyroid and parathyroid cancers grow and spread to other areas of the body. He also investigates the genetic basis of familial thyroid cancer. Dr. Clark is currently a principle investigator and co-investigator on several clinical trials concerning improving the care of patients with thyroid cancer.
Selected Publications
-
Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid. 15: 222-31, Mar/2005.
-
Shen WT, Wong TS, Chung WY, Wong MG, Kebebew E, Duh QY, Clark OH. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery. 138: 979-84; discussion 984-5, Dec/2005.
-
Caron NR, Tan YY, Ogilvie JB, Triponez F, Reiff ES, Kebebew E, Duh QY, Clark OH. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary? World J Surg. 30: 833-40, May/2006.
-
Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG, Segal MR, Kebebew E, Duh QY, Clark OH. Does familial non-medullary thyroid cancer adversely affect survival? World J Surg. 30: 787-93, May/2006.
-
Triponez F, Poder L, Zarnegar R, Goldstein R, Roayaie K, Feldstein V, Lee J, Kebebew E, Duh QY, Clark OH. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab. 91: 4943-7, Dec/2006.